GB202201708D0 - Compositions for oral delivery of biotherapeutics - Google Patents

Compositions for oral delivery of biotherapeutics

Info

Publication number
GB202201708D0
GB202201708D0 GBGB2201708.1A GB202201708A GB202201708D0 GB 202201708 D0 GB202201708 D0 GB 202201708D0 GB 202201708 A GB202201708 A GB 202201708A GB 202201708 D0 GB202201708 D0 GB 202201708D0
Authority
GB
United Kingdom
Prior art keywords
biotherapeutics
compositions
oral delivery
oral
delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2201708.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intract Pharma Ltd
Original Assignee
Intract Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intract Pharma Ltd filed Critical Intract Pharma Ltd
Priority to GBGB2201708.1A priority Critical patent/GB202201708D0/en
Publication of GB202201708D0 publication Critical patent/GB202201708D0/en
Priority to PCT/EP2023/053219 priority patent/WO2023152234A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GBGB2201708.1A 2022-02-10 2022-02-10 Compositions for oral delivery of biotherapeutics Ceased GB202201708D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2201708.1A GB202201708D0 (en) 2022-02-10 2022-02-10 Compositions for oral delivery of biotherapeutics
PCT/EP2023/053219 WO2023152234A1 (en) 2022-02-10 2023-02-09 Compositions for oral delivery of biotherapeutics

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2201708.1A GB202201708D0 (en) 2022-02-10 2022-02-10 Compositions for oral delivery of biotherapeutics

Publications (1)

Publication Number Publication Date
GB202201708D0 true GB202201708D0 (en) 2022-03-30

Family

ID=80820874

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2201708.1A Ceased GB202201708D0 (en) 2022-02-10 2022-02-10 Compositions for oral delivery of biotherapeutics

Country Status (2)

Country Link
GB (1) GB202201708D0 (en)
WO (1) WO2023152234A1 (en)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026825A (en) * 1988-09-08 1991-06-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Intranasal calcitonin formulations
GB9414699D0 (en) 1994-07-21 1994-09-07 Slagel David Aqueous foamable composition
GB0607534D0 (en) 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
WO2010050179A1 (en) * 2008-10-27 2010-05-06 Ｓｂｉアラプロモ株式会社 Prophylactic/ameliorating agent for adult diseases comprising 5-aminolevulinic acid, derivative of 5-aminolevulinic acid, or salt of 5-aminolevulinic acid or the derivative of 5-aminolevulinic acid as active ingredient
US20190375786A1 (en) * 2016-09-09 2019-12-12 Fred Hutchinson Cancer Research Center Stable peptides and methods of use thereof
GB201905940D0 (en) * 2019-04-29 2019-06-12 Intract Pharma Ltd 5-aminolevulinic acid for the local treatment of inflammatory bowel disease
GB201906917D0 (en) 2019-05-16 2019-07-03 Intract Pharma Ltd Novel compositions
GB202017863D0 (en) 2020-11-12 2020-12-30 Intract Pharma Ltd Novel compositions

Also Published As

Publication number Publication date
WO2023152234A1 (en) 2023-08-17

Similar Documents

Publication Publication Date Title
EP4087406A4 (en) Vesicle compositions for oral delivery
EP3914252A4 (en) Pharmaceutical compositions of nilotinib
EP4132511A4 (en) Pharmaceutical compositions comprising meloxicam
GB202201708D0 (en) Compositions for oral delivery of biotherapeutics
EP4126056A4 (en) New compositions for oral or nasal use
EP4122483A4 (en) Oral pharmaceutical composition
EP4135699A4 (en) Pharmaceutical compositions
FI4203919T3 (en) Lipid-based composition for oral administration of bradykinin b2-receptor antagonists
IL307194A (en) Pharmaceutical compositions comprising zolmitriptan
GB202207222D0 (en) Pharmaceutical composition for sublingual administration of clonidne
GB2610009B (en) Stable compositions for the treatment of dental caries
FI4099980T3 (en) Stable pharmaceutical compositions of ropinirole
GB202311981D0 (en) Oral compositions
GB202313738D0 (en) Pharmaceutical compositions
GB202312055D0 (en) Pharmaceutical compositions
GB202217146D0 (en) New pharmaceutical compositions
GB202217150D0 (en) New pharmaceutical compositions
GB202017315D0 (en) Formulations for transmucosal delivery of alkaloids
IN202221071152A (en) Extended-release pharmaceutical compositions of dydrogestrone
GB202017314D0 (en) Formulations for transmucosal delivery of cannabinoids
GB202210572D0 (en) Mouldable compositions
GB202007254D0 (en) Delivery device for units of an oral dosage form
AU2022395766A1 (en) Compositions for increased stability of bacteria
GB202311283D0 (en) Therapeutic compositions
GB202207263D0 (en) Therapeutic compositions

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)